SCHEMBL1324059

SCHEMBL1324059

CCOC(=O)c1noc2cc(O[Si](C(C)C)(C(C)C)C(C)C)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
SLC2A1 P11166 1/20 0.39
KDM4E B2RXH2 4/20 0.37
AKR1B1 P15121 1/20 0.37
ALDH1A1 P00352 5/20 0.37
AR P10275 1/20 0.37
POLB P06746 2/20 0.36
TARBP2 Q15633 2/20 0.36
PDCD4 Q53EL6 1/20 0.36
HTT P42858 3/20 0.36
HPGD P15428 2/20 0.36
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36
GLA P06280 1/20 0.36
CA3 P07451 1/20 0.36
GAA P10253 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491943 0.84 KDM4E (0.50) LMNAKDM4EALDH1A1TARBP2PDCD4
SCHEMBL4304519 0.84 LMNA (0.43) LMNACYP1A2KDM4EALDH1A1HPGD
SCHEMBL14492918 0.80 KDM4E (0.42) LMNACYP1A2KDM4EAKR1B1ALDH1A1
SCHEMBL492496 0.78 AKR1B1 (0.54) CYP1A2KDM4EAKR1B1ALDH1A1HTT
SCHEMBL492601 0.77 LMNA (0.46) LMNACYP1A2KDM4EAKR1B1ALDH1A1
SCHEMBL492231 0.77 TBK1 (0.48) LMNAKDM4EALDH1A1POLBTARBP2
SCHEMBL6833807 0.77 ALDH1A1 (0.50) KDM4EALDH1A1TARBP2HPGDGAA
SCHEMBL8226588 0.77 HTT (0.50) LMNAKDM4EALDH1A1HTTMLYCD
SCHEMBL1324010 0.77 MAOB (0.56) ALDH1A1HPGDMAOBMAPT
SCHEMBL1325247 0.74 PTGS2 (0.46) LMNASLC2A1ALDH1A1TDP2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058276-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2011-11-15 US disclosed
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases PHKG1, MAP3K20, CDK2 LMNA 2623/4885CYP1A2 2732/4885SLC2A1 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.